Don't miss

Replay


LATEST SHOWS

FOCUS

Iraq: The long road to rebuilding Mosul

Read more

BUSINESS DAILY

Exxon sues US over $2m fine for violating Russia sanctions

Read more

IN THE PAPERS

'Too sexy for Malaysia': Hit single 'Despacito' stirs controversy

Read more

IN THE PAPERS

Is this the end of Emmanuel Macron's honeymoon period?

Read more

MEDIAWATCH

Macron's air force uniform draws Tom Cruise comparisons

Read more

THE DEBATE

Polish democracy under threat? EU warns Warsaw over judicial independence

Read more

PEOPLE & PROFIT

Game of Thrones and TV's golden age

Read more

ENCORE!

The best of the summer's exhibitions in Paris

Read more

INSIDE THE AMERICAS

Game of Thrones returns: Mega fans bask in themed pop-up bar

Read more

Sanofi-Aventis withdraws anti-obesity drug from European shelves

Text by AFP

Latest update : 2008-10-24

EU authorities have suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent, due to an abnormal risk of psychiatric problems.

EU authorities suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent Thursday, the firm announced, adding that it had not ruled out a worldwide halt.

"Sales have been halted in all the pharmacies in the 18 countries of the European Union where it is distributed," a company spokesman told AFP.

Sanofi-Aventis said the European Medicines Agency (EMEA) had warned that patients taking the drug ran almost double the normal risk of psychiatric problems.

"The risks of taking Acomplia are now greater than the benefits that the drug can bring the patient according to its current guidelines," the company said, citing the EMEA.

Europe has allowed sales of Acomplia since 2006, but it has not been authorised in the United States where authorities believe it encourages suicidal thoughts, even in patients with no history of depression.

The company said it had not ruled out withdrawing the drug in the 14 non-EU countries where it is sold. It said users of the drug should consult a doctor or pharmacist.
 

Date created : 2008-10-24

COMMENT(S)